Shandong Xinhua Pharmaceutical Secures Drug Registration for Pentazocine Injection

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.

Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Pentazocine injection from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to proceed with the production and sale of the drug, thereby potentially enhancing its market position in the pharmaceutical industry.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, engaged in the production and distribution of prescription drugs. The company focuses on the development and marketing of chemical medicines, with a significant emphasis on domestic production.

YTD Price Performance: -1.03%

Average Trading Volume: 3,353,639

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$9.01B

For an in-depth examination of 0719 stock, go to TipRanks’ Stock Analysis page.